SMA
ALLO icon

Seven Mile Advisory’s Allogene Therapeutics ALLO Stock Holding History

Seven Mile Advisory’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30K Hold
14,434
– – 0.02% 158
2026
Q1 		$35.2K Buy
+14,434
New +$28.9K 0.03% 180
2025
Q4 		– Sell
-14,434
Closed -$17.9K – 264
2025
Q3 		$17.9K Sell
14,434
-15
-0.1% -$18 ﹤0.01% 304
2025
Q2 		$16.3K Buy
14,449
+3,979
+38% +$5.29K 0.01% 180
2025
Q1 		$15.3K Buy
+10,470
New +$19.7K 0.01% 175

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Seven Mile Advisory's ALLO Position: Q2 2026 in Review

Seven Mile Advisory held its Allogene Therapeutics (ALLO) position steady in Q2 2026 at 14,434 shares worth $30K. The position accounts for 0.02% of the portfolio, ranked #158.

Seven Mile Advisory first reported a position in ALLO in Q1 2025 and has held it in 5 quarters since. The position peaked at $35.2K in Q1 2026. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Seven Mile Advisory held 14,434 shares of Allogene Therapeutics worth $30K as of Q2 2026.
  • Seven Mile Advisory left its Allogene Therapeutics share count unchanged in Q2 2026.
  • Allogene Therapeutics made up 0.02% of Seven Mile Advisory's portfolio in Q2 2026, its #158 holding.
  • Seven Mile Advisory first reported a position in Allogene Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Seven Mile Advisory's Allogene Therapeutics position peaked at $35.2K in Q1 2026.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Seven Mile Advisory's 13F filing for Q2 2026, filed 13 Aug 2026.